VANCOUVER, B.C. –(Newsfile Corp.) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or the “Company”) is pleased to announce that the Company has received formal conditional approval from the… Read More
CAMBRIDGE, MASS. and New York, NY– Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence… Read More
VANCOUVER, BC / ACCESSWIRE / — RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FSE:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to… Read More
Vancouver, BC – Bold Therapeutics, a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug Application (IND) amendment… Read More
Applications are open for entrepreneurship@UBC’s Lab2Launch program! entrepreneurship@UBC’s Lab2Launch Venture Building program is for UBC researchers and scientists who are focusing on the development of a scientific or technological innovation… Read More
